Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Income from Continuing Operations data on record, last reported at 31836000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 104.68% year-over-year to 31836000.0; the TTM value through Sep 2025 reached 98666000.0, up 30.3%, while the annual FY2024 figure was 136701000.0, 640.77% down from the prior year.
  • Income from Continuing Operations reached 31836000.0 in Q3 2025 per TNXP's latest filing, down from 28296000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15554000.0 in Q3 2024 and bottomed at 77315000.0 in Q2 2024.
  • Average Income from Continuing Operations over 3 years is 30017909.09, with a median of 27975000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 166.59% in 2024, then surged 63.4% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 27329000.0 in 2023, then increased by 17.74% to 22480000.0 in 2024, then tumbled by 41.62% to 31836000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 31836000.0 in Q3 2025, 28296000.0 in Q2 2025, and 16054000.0 in Q1 2025.